Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Br J Dermatol. 2012 Jul;167(1):194–197. doi: 10.1111/j.1365-2133.2012.10905.x

Figure 1.

Figure 1

Time of administration of LEBT during the course of romidepsin. Five patients with symptomatic lesions received LEBT. Thin lines across for each patient represent a course of therapy with time of LEBT administration bracketed. A double vertical line at the end shows when disease progression was declared, or for patient 1, therapy with romidepsin stopped.